24-Hour time-dependent aspirin efficacy in patients with stable coronary artery disease

Thrombosis and Haemostasis

Volumn 105, Issue 2, 2011, Pages 336-344

  Henry, Patrick ^a   Vermillet, Adeline ^a   Boval, Bernadette ^b   Guyetand, Carine ^a   Petroni, Thibaut ^a   Dillinger, Jean Guillaume ^a   Sideris, Georgios ^a   Dit Sollier, Claire Bal ^b   Drouet, Ludovic ^b  

^a HÔPITAL LARIBOISIÈRE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Aspirin; Aspirin resistance; Coronary artery disease; Platelet aggregation

Indexed keywords

LYSINE ACETYLSALICYLATE; THROMBOXANE B2;

ADULT; AGED; ARTICLE; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTAGLANDIN SYNTHESIS; PROTEIN SYNTHESIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TIME;

AGED; ARACHIDONIC ACID; ASPIRIN; BLOOD PLATELETS; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PARIS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; THROMBOXANE A2; TIME FACTORS; TREATMENT OUTCOME;

EID: 79851495676     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-02-0082     Document Type: Article

References (49)

1. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
2. Campbell CL, Smyth S, Montalescot G, et al. Aspirin dose for the prevention of cardiovascular disease: a systematic review. J Am Med Assoc 2007; 297: 2018-2024. (Pubitemid 46740354)
3. Patrono C, Baigent C, Hirsh J, et al. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 199S-233S.
4. Cipollone F, Ciabattoni G, Patrignani P, et al. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 2000; 102; 1007-1013. (Pubitemid 30657517)
5. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-965. (Pubitemid 36315537)
6. Snoep JD, Hovens MM, Eikenboom JC, et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007; 154: 221-231. (Pubitemid 47069129)
7. Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. Br Med J 2008; 336: 195-198. (Pubitemid 351212675)
8. McKee SA, Sane DC, Deliargyris EN. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost 2002; 88: 711-715. (Pubitemid 35345324)
9. Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol 2005; 46: 986-993. (Pubitemid 41316504)
10. Lordkipanidze M, Pharand C, Schampaert E, et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28: 1702-1708. (Pubitemid 47227104)
11. Topol EJ, Easton D, Harrington RA, et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 2003; 108: 399-406. (Pubitemid 36935531)
12. Quinn MJ, Aronow HD, Califf RM, et al. Aspirin dose and six-month outcome after an acute coronary syndrome. J Am Coll Cardiol 2004; 43: 972-978. (Pubitemid 38352974)
13. Lee PY, Chen WH, Ng W, et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 2005; 118: 723-727. (Pubitemid 40897657)
14. Patrono C, Ciabattoni G, Patrignani P, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985; 72: 1177-1184. (Pubitemid 16126796)
15. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984; 311: 1206-1211. (Pubitemid 14021923)
16. Brantmark B, Wahlin-Boll E, Melander A. Bioavailability of acetylsalicylic acid and salicylic acid from rapid-and slow-release formulations, and in combination with dipyridamol. Eur J Clin Pharmacol 1982; 22: 309-314. (Pubitemid 12085317)
17. Awtry EH, Loscalzo J. Aspirin. Circulation 2000; 101: 1206-1218.
18. Evangelista V, Manarini S, Di Santo A, et al. De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. Circ Res 2006; 98: 593-595.
19. Sonksen JR, Kong KL, Holder R. Magnitude and time course of impaired primary haemostasis after stopping chronic low and medium dose aspirin in healthy volunteers. Br J Anaesth 1999; 82: 360-365. (Pubitemid 29112536)
20. Watala C, Golanski J, Pluta J, et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb Res 2004; 113: 101-113. (Pubitemid 38534487)
21. Lucas AR, Korol R, Pepine CJ. Inflammation in atherosclerosis: some thoughts about acute coronary syndromes. Circulation 2006; 113: e728-732.
22. Montalescot G, Sideris G, Meuleman C, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 2006; 48: 931-938. (Pubitemid 44292463)
23. Patrono C, Ciabattoni G, Pinca E, et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980; 17: 317-327. (Pubitemid 10129020)
24. Heidemann DR, Schulenberg ES, Smith WH. Determination of aspirin and salicylic acid by reverse-phase liquid chromatography. J Assoc Off Anal Chem 1987; 70: 964-966.
25. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. Am J Cardiol 2006; 97: 38-43. (Pubitemid 41828120)
26. Cotter G, Shemesh E, Zehavi M, et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J. 2004; 147: 293-300.
27. Valles J, Santos MT, Fuset MP, et al. Partial inhibition of platelet thromboxane A2 synthesis by aspirin is associated with myonecrosis in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2007; 99: 19-25. (Pubitemid 44969337)
28. Di Minno G, Silver MJ, Murphy S. Monitoring the entry of new platelets into the circulation after ingestion of aspirin. Blood 1983; 61: 1081-1085. (Pubitemid 13099894)
29. Cerletti C, Dell'Elba G, Manarini S, et al. Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes. Clin Pharmacokinet 2003; 42: 1059-1070. (Pubitemid 37186677)
30. Perneby C, Wallen NH, Rooney C, et al. Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost 2006; 95: 652-658.
31. Lordkipanidze M, Pharand C, Schampaert E, et al. Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease. Int J Cardiol 2010; prepub online.
32. Schwartz KA, Schwartz DE, Barber K, et al. Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients. J Transl Med 2008; 6: 46.
33. Cuisset T, Frere C, Quilici J, et al. Aspirin noncompliance is the major cause of "aspirin resistance" in patients undergoing coronary stenting. Am Heart J 2009; 157: 889-893.
34. Wurtz M, Grove EL, Kristensen SD, et al. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart 96: 368-371.
35. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-1817.
36. Crescente M, Cerletti C, de Gaetano G. Gallic acid, a dietary polyphenolic component, blunts the inhibition of platelet COX-1 by aspirin: preliminary in-vitro findings. Thromb Haemost 2007; 97: 1054-1056. (Pubitemid 46939224)
37. Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther 2003; 73: 122-130. (Pubitemid 36158493)
38. Macchi L, Christiaens L, Brabant S, et al. Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms. J Am Coll Cardiol 2003; 42: 1115-1119. (Pubitemid 37108603)
39. Lordkipanidze M, Diodati JG, Turgeon J, et al. Platelet count, not oxidative stress, may contribute to inadequate platelet inhibition by aspirin. Int J Cardiol 2010; 143: 43-50.
40. Patrono C, Rocca B. Drug insight: aspirin resistance - fact or fashion? Nat Clin Pract Cardiovasc Med 2007; 4: 42-50.
41. FitzGerald GA, Brash AR, Oates JA, et al. Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man. J Clin Invest 1983; 72: 1336-1343. (Pubitemid 13013765)
42. Dragani A, Pascale S, Recchiuti A, et al. The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. Blood 2010; 115: 1054-1061.
43. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993; 71: 397-403.
44. Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994; 25: 2331-2336. (Pubitemid 24359298)
45. Mehta SS, Silver RJ, Aaronson A, et al. Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus. Am J Cardiol 2006; 97: 567-570. (Pubitemid 43190052)
46. Grove EL, Hvas AM, Johnsen HL, et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost 2010; 103: 1245-1253.
47. Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007; 50: 1822-1834. (Pubitemid 350007957)
48. Gurbel PA, Bliden KP, DiChiara J, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007; 115: 3156-3164. (Pubitemid 47012230)
49. Pulcinelli FM, Riondino S, Celestini A, et al. Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin. J Thromb Haemost 2005; 3: 2784-2789. (Pubitemid 41819808)